Award recognises innovative label-free technology
A Frost & Sullivan award has been given to a new label-free single-cell analysis and sorting platform for utilising cutting-edge technologies.
List view / Grid view
A Frost & Sullivan award has been given to a new label-free single-cell analysis and sorting platform for utilising cutting-edge technologies.
Researchers have used stem cells, CRISPR and gene sequencing technology to create the basis of a new brain cancer model that could offer opportunities for drug discovery.
The Cubis® II balance, with pharma package, contains all the technical controls to support compliance with common regulations.
Researchers have produced a mathematical framework enabling quick assessment of how different parameters control interactions between molecules with multiple binding sites.
Laboratory Information Management Systems (LIMS) is becoming increasingly important in GMP regulated environments in order to ensure data integrity and faster working practices.
Researchers have created an algorithm that locates and analyses DNA structures which are linked to the development of certain diseases.
Endogenous human antibodies can be used to build and dismantle 2D and 3D DNA nanostructures, finds new research.
A survey has shown that the pharmaceutical industry believes R&D will see a lot of benefit from digital transformation and that AI will be at the forefront.
Self-learning microscopy opens new horizons in high-content analysis and advances phenotypic screening.
Scientists have idenified that variation in a gene called Mucin 6 appears to indicate a tendency for acquiring Alzheimer’s disease.
New software has been developed that can reveal the detailed RNA-binding properties of proteins, which is important for characterising the pathology of many diseases.
Researchers have created an AI model that analyses the citations of studies, predicting their potential for eventual clinical application.
A new platform brings together genome editing with magnetic cell sorting to reveal new drug targets for cancer and regenerative medicine.
A new platform combines AI, flow chemistry and robotics to minimise the need for human intervention in the synthesis process.
Marc Baiget-Francesch highlights interesting developments in the field of protein drug design and explains how continual software improvements are speeding up the process.